📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
3 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
BULLISH
TOTAL VIEWS
5
RECENT COVERAGE · 4 ARTICLES
Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value
Nurix Therapeutics (NRIX) received a price target increase from Baird, raising the valuation guidance to $33 from $26 while maintaining...
Truist is Bullish on Nurix Therapeutics, Inc. (NRIX)
Truist analyst Gregory Renza elevated confidence in NRIX by raising the price target modestly from $30 to $32, representing a 6.7%...
Truist is Bullish on Nurix Therapeutics, Inc. (NRIX)
Truist analyst Gregory Renza's price target increase for NRIX from $30 to $32 reflects incremental confidence in the biotech company's...
Nurix Therapeutics Deal With Roche Is Worth Betting On (NASDAQ:NRIX)
NRIX announced a partnership with pharmaceutical giant Roche, representing validation of its lead candidate bexobrutinib and potential...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice